On Feb. 16, 361Firm haosts a Deep Dive on the international cannabis and CBD markets in the wake of GW Pharma's acquisition and Tilray’s UK distribution deal. To register, join the Cannabis group on 361’s App (https://361firm.honeycommb.com/groups/cannabis).
Anand Shahi, President of Bar Capital, a thought leader that invests in, advises, and raises funding for companies across the cannabis industry.
Jamie Blundell, CEO of Segra International, a Canadian cannabis tissue culture company supplying pest and disease resistant plantlets and genetics to cannabis cultivators globally. Segra is a leader in solving consistency and yield optimization challenges for cannabis cultivators.
Brian Sheng and John Downs, CEO and EVP of Asia Horizon, a retail CBD distributor in China that has secured a limited license to process Active Pharmaceutical Ingredients for the Asian, European and North American markets.
Ben Langley and Kalad Shah, CEO and CFO of Grow Group respectively, and Pierre van Weperen, CEO of Grow Pharma. Grow is focused on the medical cannabis market in the UK and Europe and is the partner of Tilray in the UK medical distribution deal announced recently.